US bid to limit who can prescribe mifepristone

7 February 2001

Two US Republican Congressmen are proposing legislation which would setlimits on the physicians who would be able to prescribe the controversial abortion drug mifepristone.

The legislation, offered by Senator Tim Hutchinson and Representative David Vitter, says prescribing physicians should not only be legally authorized to perform abortions but also qualified to deal with complications arising from incomplete abortions. They must also have admitting privileges at a hospital nearby, reports the Associated Press.

The Food and Drug Administration finally approved the drug, trade-named Mifeprex, ilaat fall (Marketletter October 9, 2000), after years of political wrangling, and private company Danco Laboratories began shipping it to physicians on November 20.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight